Free Trial

Almitas Capital LLC Acquires Shares of 1,050,520 Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Lyell Immunopharma logo with Medical background

Almitas Capital LLC bought a new stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 1,050,520 shares of the company's stock, valued at approximately $672,000. Almitas Capital LLC owned approximately 0.36% of Lyell Immunopharma at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. RPO LLC purchased a new position in Lyell Immunopharma during the fourth quarter worth $42,000. Wells Fargo & Company MN grew its position in shares of Lyell Immunopharma by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock valued at $60,000 after purchasing an additional 20,542 shares during the period. SG Americas Securities LLC grew its holdings in Lyell Immunopharma by 102.8% in the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock valued at $75,000 after buying an additional 59,182 shares during the period. Barclays PLC increased its position in Lyell Immunopharma by 7.4% during the fourth quarter. Barclays PLC now owns 258,380 shares of the company's stock worth $165,000 after purchasing an additional 17,765 shares during the last quarter. Finally, Boothbay Fund Management LLC boosted its holdings in shares of Lyell Immunopharma by 190.4% in the 4th quarter. Boothbay Fund Management LLC now owns 406,234 shares of the company's stock valued at $260,000 after purchasing an additional 266,354 shares during the last quarter. Hedge funds and other institutional investors own 66.05% of the company's stock.

Insider Activity

In related news, CFO Charles W. Newton purchased 200,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $0.56 per share, with a total value of $112,000.00. Following the purchase, the chief financial officer now owns 200,000 shares of the company's stock, valued at $112,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard Klausner purchased 158,000 shares of the business's stock in a transaction dated Friday, March 14th. The shares were purchased at an average price of $0.60 per share, for a total transaction of $94,800.00. Following the acquisition, the director now directly owns 843,365 shares of the company's stock, valued at $506,019. This trade represents a 23.05 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 768,640 shares of company stock worth $449,508. 25.10% of the stock is owned by company insiders.

Lyell Immunopharma Stock Down 3.3 %

LYEL stock traded down $0.01 during midday trading on Wednesday, reaching $0.40. The company had a trading volume of 157,608 shares, compared to its average volume of 1,034,824. Lyell Immunopharma, Inc. has a fifty-two week low of $0.39 and a fifty-two week high of $2.88. The stock has a 50 day moving average price of $0.52 and a 200 day moving average price of $0.70. The firm has a market capitalization of $118.73 million, a PE ratio of -0.51 and a beta of -0.25.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The firm had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. Research analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "neutral" rating and set a $1.00 price target on shares of Lyell Immunopharma in a research report on Wednesday, April 16th.

Check Out Our Latest Research Report on Lyell Immunopharma

About Lyell Immunopharma

(Free Report)

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

Further Reading

Institutional Ownership by Quarter for Lyell Immunopharma (NASDAQ:LYEL)

Should You Invest $1,000 in Lyell Immunopharma Right Now?

Before you consider Lyell Immunopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.

While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines